These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 37115038)

  • 1. Molecular and clinicopathologic characterization of pediatric histiocytoses.
    Hélias-Rodzewicz Z; Donadieu J; Terrones N; Barkaoui MA; Lambilliotte A; Moshous D; Thomas C; Azarnoush S; Pasquet M; Mansuy L; Aladjidi N; Jeziorski E; Marec-Berard P; Gilibert-Yvert M; Spiegel A; Saultier P; Pellier I; Pagnier A; Pertuisel S; Poiree M; Bodet D; Millot F; Isfan F; Stephan JL; Leruste A; Rigaud C; Filhon B; Carausu L; Reguerre Y; Kieffer I; Brichard B; Ben Jannet R; Bakari M; Idbaih A; Bodemer C; Cohen-Aubart F; Haroche J; Tazi A; Boudjemaa S; Fraitag S; Emile JF; Heritier S;
    Am J Hematol; 2023 Jul; 98(7):1058-1069. PubMed ID: 37115038
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BRAF V600E mutation in Juvenile Xanthogranuloma family neoplasms of the central nervous system (CNS-JXG): a revised diagnostic algorithm to include pediatric Erdheim-Chester disease.
    Picarsic J; Pysher T; Zhou H; Fluchel M; Pettit T; Whitehead M; Surrey LF; Harding B; Goldstein G; Fellig Y; Weintraub M; Mobley BC; Sharples PM; Sulis ML; Diamond EL; Jaffe R; Shekdar K; Santi M
    Acta Neuropathol Commun; 2019 Nov; 7(1):168. PubMed ID: 31685033
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of
    Razanamahery J; Godot A; Leguy-Seguin V; Samson M; Audia S; Bonnotte B
    Front Immunol; 2023; 14():1260193. PubMed ID: 37809108
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses.
    Haroche J; Charlotte F; Arnaud L; von Deimling A; Hélias-Rodzewicz Z; Hervier B; Cohen-Aubart F; Launay D; Lesot A; Mokhtari K; Canioni D; Galmiche L; Rose C; Schmalzing M; Croockewit S; Kambouchner M; Copin MC; Fraitag S; Sahm F; Brousse N; Amoura Z; Donadieu J; Emile JF
    Blood; 2012 Sep; 120(13):2700-3. PubMed ID: 22879539
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systemic Histiocytosis (Langerhans Cell Histiocytosis, Erdheim-Chester Disease, Destombes-Rosai-Dorfman Disease): from Oncogenic Mutations to Inflammatory Disorders.
    Papo M; Cohen-Aubart F; Trefond L; Bauvois A; Amoura Z; Emile JF; Haroche J
    Curr Oncol Rep; 2019 May; 21(7):62. PubMed ID: 31115724
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis.
    Chakraborty R; Hampton OA; Shen X; Simko SJ; Shih A; Abhyankar H; Lim KP; Covington KR; Trevino L; Dewal N; Muzny DM; Doddapaneni H; Hu J; Wang L; Lupo PJ; Hicks MJ; Bonilla DL; Dwyer KC; Berres ML; Poulikakos PI; Merad M; McClain KL; Wheeler DA; Allen CE; Parsons DW
    Blood; 2014 Nov; 124(19):3007-15. PubMed ID: 25202140
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Status of Langerhans cell histiocytosis in children and adults].
    Kudo K
    Rinsho Ketsueki; 2019; 60(9):1308-1316. PubMed ID: 31597857
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of the BRAF and MAP2K1 mutations in patients with Langerhans cell histiocytosis in Japan.
    Hayase T; Saito S; Shioda Y; Imamura T; Watanabe K; Ohki K; Yoshioka T; Oh Y; Kawahara Y; Niijima H; Imashuku S; Morimoto A
    Int J Hematol; 2020 Oct; 112(4):560-567. PubMed ID: 32654047
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biological and clinical significance of somatic mutations in Langerhans cell histiocytosis and related histiocytic neoplastic disorders.
    Allen CE; Parsons DW
    Hematology Am Soc Hematol Educ Program; 2015; 2015():559-64. PubMed ID: 26637772
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pediatric Langerhans cell histiocytosis: the impact of mutational profile on clinical progression and late sequelae.
    Nann D; Schneckenburger P; Steinhilber J; Metzler G; Beschorner R; Schwarze CP; Lang P; Handgretinger R; Fend F; Ebinger M; Bonzheim I
    Ann Hematol; 2019 Jul; 98(7):1617-1626. PubMed ID: 30923995
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Langerhans cell histiocytosis and Erdheim-Chester disease, both with cutaneous presentations, and papillary thyroid carcinoma all harboring the BRAF(V600E) mutation.
    Johnson WT; Patel P; Hernandez A; Grandinetti LM; Huen AC; Marks S; Ho J; Monaco SE; Jaffe R; Picarsic J
    J Cutan Pathol; 2016 Mar; 43(3):270-5. PubMed ID: 26454140
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Uncommon histiocytic disorders: Rosai-Dorfman, juvenile xanthogranuloma, and Erdheim-Chester disease.
    Haroche J; Abla O
    Hematology Am Soc Hematol Educ Program; 2015; 2015():571-8. PubMed ID: 26637774
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    Ozer E; Sevinc A; Ince D; Yuzuguldu R; Olgun N
    Pediatr Dev Pathol; 2019 Oct; 22(5):449-455. PubMed ID: 31072207
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High prevalence of somatic MAP2K1 mutations in BRAF V600E-negative Langerhans cell histiocytosis.
    Brown NA; Furtado LV; Betz BL; Kiel MJ; Weigelin HC; Lim MS; Elenitoba-Johnson KS
    Blood; 2014 Sep; 124(10):1655-8. PubMed ID: 24982505
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic landscape of adult Langerhans cell histiocytosis with lung involvement.
    Jouenne F; Chevret S; Bugnet E; Clappier E; Lorillon G; Meignin V; Sadoux A; Cohen S; Haziot A; How-Kit A; Kannengiesser C; Lebbé C; Gossot D; Mourah S; Tazi A
    Eur Respir J; 2020 Feb; 55(2):. PubMed ID: 31806714
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BRAF V600E mutation in pediatric intracranial and cranial juvenile xanthogranuloma.
    Techavichit P; Sosothikul D; Chaichana T; Teerapakpinyo C; Thorner PS; Shuangshoti S
    Hum Pathol; 2017 Nov; 69():118-122. PubMed ID: 28504206
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cutaneous adult xanthogranuloma with a small portion of BRAF
    Ishikawa M; Endo Y; Uehara A; Suto M; Yasuda M; Motegi SI; Ishikawa O
    J Dermatol; 2019 Feb; 46(2):161-165. PubMed ID: 30536719
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of both Langerhans cell histiocytosis and Erdheim-Chester disease linked to the BRAFV600E mutation.
    Hervier B; Haroche J; Arnaud L; Charlotte F; Donadieu J; Néel A; Lifermann F; Villabona C; Graffin B; Hermine O; Rigolet A; Roubille C; Hachulla E; Carmoi T; Bézier M; Meignin V; Conrad M; Marie L; Kostrzewa E; Michot JM; Barete S; Taly V; Cury K; Emile JF; Amoura Z;
    Blood; 2014 Aug; 124(7):1119-26. PubMed ID: 24894769
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of Langerhans cell histiocytosis: role of BRAF/MAPK inhibition.
    Abla O; Weitzman S
    Hematology Am Soc Hematol Educ Program; 2015; 2015():565-70. PubMed ID: 26637773
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mixed Langerhans Cell Histiocytosis and Erdheim-Chester Disease in a Girl: A Rare and Puzzling Diagnosis.
    Ocak S; Bayramoglu Z; Tugcu D; Karaman S; Unuvar A; Karakas Z
    J Pediatr Hematol Oncol; 2021 Apr; 43(3):e375-e379. PubMed ID: 32097280
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.